M. Rutten-Van Molken (Rotterdam, Netherlands), B. Nybo Jensen (Copenhagen, Denmark)
Asthma burden in the hospital setting in Australia
L. Watson, F. Turk, K. F Rabe (Manchester, United Kingdom; Basel, Switzerland; Leiden, Netherlands)
|   |
Clinic-economical analysis of the six-part asthma management program (GINA) efficiency in polyclinic
A. Petukhova, E. Beltyukov (Yekaterinburg, Russian Federation)
| |
Cost-effectiveness of eNO measurements in chronic asthma management
M. Bischof, J. Leuppi (Basel, Switzerland)
| |
Budesonide/formoterol provides better efficacy at a lower or similar cost as compared to high-dose salmeterol/fluticasone treatment
J. Bousquet, M. Miravitlles, A. Wirén (Montpellier, France; Barcelona, Spain; Lund, Sweden)
| |
Analysis of the patient-reported outcome (PRO) endpoints found in labeling claims of asthma drugs in Europe
M. Caron, M. P. Emery, P. Marquis, E. Piault (Lyon, France; Boston, United States Of America)
| |
Cost-effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: adaptation of INNOVATE and ETOPA data to the Netherlands
R. Brown, F. Turk, M. Groot, P. Dale (London, United Kingdom; Basel, Switzerland; Arnhem, Netherlands)
| |
The 1-year cost-effectiveness of roflumilast for the treatment of severe to very severe COPD patients
M. Rutten-van Molken, F. Van Nooten, M. Lindemann, M. Caeser (Rotterdam, Netherlands; Konstanz, Germany)
| |
Is treatment with ICS and LABA good value for money for COPD? Multinational cost-effectiveness analysis of the TORCH study
H. Glick, A. Briggs, G. Lozano-Ortega, M. Spencer, P. Calverley, J. Vestbo (Philadelphia, United States Of America; Glasgow, Greenford, Liverpool, Manchester, United Kingdom; Vancouver, Canada)
| |
Active tobacco smoking and costs of COPD exacerbations in secondary medical care in Poland
T. Targowski, K. Jahnz-Rozyk, S. From, T. Plusa (Warsaw, Poland)
| |
Manner of treatment and costs of COPD exacerbations in secondary medical care in Poland
K. Jahnz-Rozyk, T. Targowski, S. From, T. Plusa (Warsaw, Poland)
| |
Direct and indirect costs of COPD treatment in primary and secondary care in Poland
K. Jahnz-Rozyk, T. Targowski, S. From (Warsaw, Poland)
| |
Cost of treatment failure in community-acquired pneumonia
S. Ott, T. Welte, C. Ernen, H. Kothe, T. Bauer (Berlin, Hannover, Burscheid, Lubeck, Germany)
| |
Quality and costs of paediatric sleep studies in community and hospital settings
J. James, S. Byrne, H. Evans (Cardiff, United Kingdom)
| |
Incident reporting system in a pneumology unit
E. C. Legorini, S. Pierotti, G. Milani (Rovigo, Italy)
| |
Descriptive analysis of 1000 clinical trials. Profile of the clinical research with medicines in 2000 in the area of a universitary hospital
E. Fernandez De Uzquiano, P. Lavilla Uriol, A. Gil Aguado, J. Frías Iniesta, F. Gaya Moreno, R. Madero Jarabo, R. Álvarez-Sala Walther (Madrid, Spain)
| |
Clinical research with medicines in the medical area of a universitary hospital. Analysis of 621 clinical trials of the medical area
E. Fernández De Uzquiano, P. Lavilla Uriol, A. Gil Aguado, J. Frías Iniesta, F. Gaya Moreno, R. Madero Jarabo, R. Alvarez-Sala Walther (Madrid, Spain)
| |
Audit to establish accuracy of diagnostic coding on discharge summaries and financial implications of errors in medical patients at the William Harvey Hospital
M. Corrigan, K. Hurt (Ashford, Kent, United Kingdom)
| |
Use of health outcomes questionnaires: authorship and copyright issues. Examples in the respiratory field
C. Anfray, M. P. Emery (Lyon, France)
| |